|
|
Post by joeypotsandpans on Nov 5, 2015 12:29:00 GMT -5
I just sold some more Jan16 4P's - unbelievable premium - $1.85. Shares will only cost $2.15 if put. Very appropriate avatar....looks like me only I'm licking my chops instead of my paws  |
|
|
|
Post by joeypotsandpans on Nov 5, 2015 11:50:26 GMT -5
Have several bids in today, shares and LEAPS...been waiting for this, keep looking at the long term charts, matter of perspective but thing of beauty if you're a technician.
|
|
|
|
Post by joeypotsandpans on Nov 4, 2015 16:48:29 GMT -5
Have you looked at Mr. Butt's record in predicting MNKD stock prices? With a history of misses like his, I can't imagine why he still has a job. He still has job because his "public" record is not what counts rather how much he adds to the bottom line of the firm, and as we have publicly witnessed with GS (the role model lol) these firms will sell their mother for a profit let alone what they portray to the public. |
|
|
|
Post by joeypotsandpans on Nov 4, 2015 15:02:30 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, some of its retail investors sabotaging the company by lending their shares to shorts, a partner that apparently is doing little other than set up trials with other drugs and has a secret plan that know else knows about, poor sales data, and a management team that appears to be acting not in the best interest of the stockholders, or their own product for that matter..regardless of what Matt said during the last CC. I looked back and saw that I bought a thousand shares almost ten years ago for just over $2.50/shr...not a lot of progress. My guess is the company gets delisted and put on the pinks by the end of the first quarter of. 2016...just my opinion based on past history. Unfortunately your "opinion" carries slightly lower credence than Adnan as my bid continues to sit from the opening bell....but thanks for chiming in lol  |
|
|
|
Post by joeypotsandpans on Nov 4, 2015 12:29:59 GMT -5
How are those MNKD dividends this week? Fed is at zero interest rates...MNKD shorts @ 38-40%....with Yellen jawboning again this morning about moving possibility in Dec. Lol...let me tell you that first time homebuyers are getting free down payment assistance at what remains some of the lowest rates in years and housing is in balance at best...no way they can remove the heroin from both wall and main street...trapped just like the 45-50% of float on the wrong side...expecting more fictional "shoe(s)" to drop by both Janet and the shorts....volume remains anemic even after the "dramatic downgrade" |
|
|
|
Post by joeypotsandpans on Nov 4, 2015 7:27:16 GMT -5
With this kind of downgrade, would the analyst, as part of his/her employer's protocol be required to discuss this with any higher ups prior to releasing it? Furthermore, I re-read his report as posted here and on investors hub and am wondering if he was not encouraged to write this piece. If others pile on today and tomorrow and drive the price below $2.00, will any of you add shares? Please see earlier post in this thread Cocked, Locked, and ready to Rock!! (Albeit via LEAPS most likely) |
|
|
|
Post by joeypotsandpans on Nov 3, 2015 22:12:08 GMT -5
This is how wall street works...pretty transparent, let's put out the downgrade for the swoosh to accumulate... don't forget about the key paragraph in the analysis...otherwise known as the "hedge" statement as follows: What would make us constructive again...... Note: all factors including "SNY stating on Nov 6 they are still fully committed... etc etc. I will be adding (again) hopefully the spreads come in on the LEAPS ...TY Mr. BUTTCAKES for the wakeup call been waiting for ya help for the flush out, falls right into the chart timing...lets get the rest of the whores to jump on the bandwagon and remind all of the pre ADCOM panic days ...Oh yeah BTW guess you got the memo (thus the hedge statement)...they are as committed as ever according to the rep I and others know....unless of course they are putting on quite the charade to their sales force..." Hard to Believe" |
|
|
|
Post by joeypotsandpans on Oct 27, 2015 17:10:50 GMT -5
CNBC put out their 50 disruptors for 2015 ( www.cnbc.com/id/102609977 ), of course MNKD cannot be on there as these are private companies so it's not mind boggling that they are not on the list but the company that is ranked 29th Intarcia Therapeutics is as they just raised a 225 million private placement for their implantable "matchstick" pump. It went through its first two of four phase III trials and it showed after 39 weeks that it dropped A1c 's vs. placebo from 10's to 7's with its GLP-1 (Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. www.prnewswire.com/news-releases/intarcia-announces-two-positive-phase-3-trials-for-itca-650-in-type-2-diabetes-freedom-1-and-freedom-1-high-baseline-hbl-study-results-277838961.html ) So here is why its mind boggling...when interviewed they talked about how they expect a 5.5 billion valuation in the not too distant future (they are hopeful to have it in the market some time in 2017 btw, perhaps someone should tell them by no means should they make any changes to the design.) While here we sit with an insulin that is showing to take A1c's to unprecedented levels in the early adopters ie., Sam,Brian, & now Jackie (can't leave out Spiro too) within 90 days. Ironically, their private placement came just a couple of days before the SNY and MNKD conf. calls, but it wouldn't surprise me who the brokerage houses are that are looking to do their IPO and tout them up to that 5.5 billion valuation. It looks like they are going to target the type II's who would still have to take orals in conjunction with the implanted pumps, at least that's the way I read it. Either way, it looks like our little disruptor is not only stepping on the toes of current BP but the upstarts as well Btw, JPG it looks like your estimate of 2017 was closer to the mark: mnkd.proboards.com/post/10647Apologize in advance if this has been brought up since I saw it last Friday but after glancing through the board which I have not had much time to do lately I didn't see it mentioned. Last Friday Cramer had on his show I believe the CEO of Intarcia and actually had him show the audience the implantation of the device and review the "benefits" it will have as a "disruptive" technology for specifically T2 diabetics. One thing that stood out to me was the CEO stated that currently the only options available for T2's was injection and oral meds taken daily....no mention whatsoever of inhalable (obviously considered another disruptive technology). They went on to talk about how it would be a viable competitor to existing BP's with respect to treating Diabetes and potentially other chronic diseases through its implantable pump. It still makes one chuckle to see him endorse a privately held company that has yet to come to market versus his skeptical attitude and projected cynicism directed toward MNKD whenever asked. So it wouldn't surprise me to see this as the beginning of the "dog and pony" show leading up to a soon to be IPO IMO. Oh yeah btw, exenatide which is currently being used as Byetta and Bydureon has an interesting history regarding its side effects, labeling, etc. with various concerns and statements from the FDA in the past... www.byettahcp.com/dosing-and-administration ....looks to me like nothing still compares to plain old human insulin but just found it interesting how much Cramer/CNBC have mentioned this "up and coming" disruptor ...pass me the tin foil hat please |
|
|
|
Post by joeypotsandpans on Oct 23, 2015 10:58:35 GMT -5
I'm sure you will start seeing the TEVA thesis now as they are the largest generic pharmaceutical company in the world... As the leading generic pharmaceutical company in the world, Teva is pleased to offer the largest portfolio of safe, effective, and FDA-approved generic products on the market. Approximately 375 Teva medicines are currently available, covering all major therapeutic categories. - See more at: www.tevagenerics.com/products/product-search#sthash.2OCeBkSR.dpufLots of potential technosphere apps possible so the speculation will continue to run rampant...anyone familiar with Copaxone It is used via needle injection for MS and when my brother in law comes to visit, it is in the refrigerator at all times: Copaxone is given as an injection under your skin. You may be given instructions on how to inject your medicine at home. Do not use this medicine at home if you do not fully understand how to give the injection and properly dispose of needles and syringes used in giving the medicine. Some people receiving a Copaxone injection have had a severe reaction. Tell your caregiver right away if you feel anxious, warm, itchy, tingly, or have a pounding heartbeat, tightness in your throat, or trouble breathing during the injection. This type of reaction may occur even after you have been using this medicine for several months. Ok, enough pumping from me today |
|
|
|
Post by joeypotsandpans on Oct 23, 2015 9:48:46 GMT -5
MannKind's shares are anticipated to be included in five TASE equity indexes: TASE's TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed.
The inclusion in these indices should mean shares will be acquired by any funds tied to these just like in US...think of the Russell rebalancing etc.
|
|
|
|
Post by joeypotsandpans on Oct 9, 2015 15:11:58 GMT -5
9/30/2015 126,841,527 4,992,693
25.405433
About status quo
|
|
|
|
Post by joeypotsandpans on Oct 9, 2015 13:59:29 GMT -5
Any takers on 130mill+ reported after the close?...what's Fidelity at today 27% to lender?...Schwab 23.5%?
|
|
|
|
Post by joeypotsandpans on Oct 8, 2015 12:48:42 GMT -5
LOL! I think at least half a dozen of you need to read and understand what a blackout period is EOM (Not directed at you petech, we posted about the same time)....as far as the term "last quarter ending" you may be right but I wouldn't be surprised if they didn't use the ATM in the interim depending on when they received the shares back from BofA. I would be surprised if they didn't replenish a portion of the cash in some fashion.
|
|
|
|
Post by joeypotsandpans on Oct 8, 2015 12:39:11 GMT -5
Once again, after being wrong/very misleading several times in the past...you all know who/what I'm referring to, Matt states that at quarter end (and unless there is a new calendar that I'm not aware of) that would be 9/30 the company had $107m in cash....which alluded to Matt quoting Mark Twain and countering those predicting the company's running out of cash and demise. So of course, you can expect his/its usual backtracking etc.
So there may have been some use of the ATM for minimal dilution to make up part of the $50m, overall for me (for those of you who are following) it's stay the course and continue to accumulate shares on the dips and waiting on '18 call options to open. It wouldn't surprise me to see further dips, not because there is any reason other than sympathetic drops with the biotechs as the indices continue to test possible new lows. The broader market may still have further to go as well which would continue to pressure what was historically high margin levels. On the other hand, float in MNKD continues to be tight with the rates to borrow in the low to mid 20's rates continue to be collected by those longs willing to wait until the inevitable (IMO) market capture.
|
|
|
|
Post by joeypotsandpans on Oct 8, 2015 11:43:04 GMT -5
They are having problems with the video, it is delayed, should start shortly, room is packed...twice as many people as seats
|
|
